Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis

With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. There are isolated case reports and series that document a milder course of COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraju, Pugazhenthan, Venkatesan, Nanditha, Sudha, T. Y. Sree, Venkatesan, Sajitha, Thangaraju, Eswaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483051/
https://www.ncbi.nlm.nih.gov/pubmed/32935079
http://dx.doi.org/10.1007/s42399-020-00510-x
_version_ 1783580898222931968
author Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Sudha, T. Y. Sree
Venkatesan, Sajitha
Thangaraju, Eswaran
author_facet Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Sudha, T. Y. Sree
Venkatesan, Sajitha
Thangaraju, Eswaran
author_sort Thangaraju, Pugazhenthan
collection PubMed
description With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. There is also an ongoing debate regarding the continuation of biologicals in the COVID patient. In this article, a non-systematic critical analysis of dupilumab was performed to delve into this hypothesis further.
format Online
Article
Text
id pubmed-7483051
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74830512020-09-11 Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis Thangaraju, Pugazhenthan Venkatesan, Nanditha Sudha, T. Y. Sree Venkatesan, Sajitha Thangaraju, Eswaran SN Compr Clin Med Covid-19 With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. There is also an ongoing debate regarding the continuation of biologicals in the COVID patient. In this article, a non-systematic critical analysis of dupilumab was performed to delve into this hypothesis further. Springer International Publishing 2020-09-10 2020 /pmc/articles/PMC7483051/ /pubmed/32935079 http://dx.doi.org/10.1007/s42399-020-00510-x Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Thangaraju, Pugazhenthan
Venkatesan, Nanditha
Sudha, T. Y. Sree
Venkatesan, Sajitha
Thangaraju, Eswaran
Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title_full Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title_fullStr Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title_full_unstemmed Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title_short Role of Dupilumab in Approved Indications of COVID-19 Patient: an Efficacy-Based Nonsystematic Critical Analysis
title_sort role of dupilumab in approved indications of covid-19 patient: an efficacy-based nonsystematic critical analysis
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483051/
https://www.ncbi.nlm.nih.gov/pubmed/32935079
http://dx.doi.org/10.1007/s42399-020-00510-x
work_keys_str_mv AT thangarajupugazhenthan roleofdupilumabinapprovedindicationsofcovid19patientanefficacybasednonsystematiccriticalanalysis
AT venkatesannanditha roleofdupilumabinapprovedindicationsofcovid19patientanefficacybasednonsystematiccriticalanalysis
AT sudhatysree roleofdupilumabinapprovedindicationsofcovid19patientanefficacybasednonsystematiccriticalanalysis
AT venkatesansajitha roleofdupilumabinapprovedindicationsofcovid19patientanefficacybasednonsystematiccriticalanalysis
AT thangarajueswaran roleofdupilumabinapprovedindicationsofcovid19patientanefficacybasednonsystematiccriticalanalysis

Ejemplares similares